查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
癌症單克隆抗體市場規模、份額和趨勢分析報告：按類型（嵌合抗體、人源化抗體）、按應用（血癌、乳腺癌、肺癌）、按最終用戶、按地區、按細分市場，2022-2030
市場調查報告書
商品編碼
1114173

癌症單克隆抗體市場規模、份額和趨勢分析報告：按類型（嵌合抗體、人源化抗體）、按應用（血癌、乳腺癌、肺癌）、按最終用戶、按地區、按細分市場，2022-2030

Cancer Monoclonal Antibodies Market Size, Share & Trends Analysis Report By Type (Chimeric Antibodies, Humanized Antibodies), By Application (Blood Cancer, Breast Cancer, Lung Cancer), By End-user, By Region, And Segment Forecasts, 2022 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

癌症單克隆抗體市場的增長和趨勢

Grandview Research 的一份新報告顯示，到 2030 年，全球癌症單克隆抗體市場預計將達到 1597 億美元。

從 2022 年到 2030 年，市場預計將以 11.2% 的複合年增長率增長。癌症患病率上升、產品批准以及強大的管道是推動市場增長的主要因素。此外，預計該領域研發資金的增加將影響該行業的增長。此外，蓬勃發展的生物仿製藥市場預計將在預測期內提供更多有利可圖的機會。

非小細胞肺癌 (NSCLC) 是一種常見的肺癌類型。只有約 8% 的轉移性 NSCLC 患者在確診後存活 5 年或更長時間，大多數情況下預後較差。此外，目前還沒有針對 HER2 的治療藥物被批准用於治療 HER2 突變的非小細胞肺癌，大約 2-4% 的非鱗狀非小細胞肺癌患者存在這種情況。然而，過去兩年取得了進展，主要是在一線治療方面，但仍有大量未滿足的醫療需求。例如，2022 年 4 月，第一三共和阿斯利康在美國接受了 Enhertu 的生物製品許可補充申請（sBLA），用於治療成人不可切除的 NSCLC。

過去三年來，單克隆抗體的開發在臨床和技術上都取得了長足的進步。由於其安全性、特異性和有效性等優點，現已被廣泛接受為先進的治療藥物。尤其是癌症，是最重要的藥物應用，佔單克隆抗體相關研發項目的近 50%。

2021 年 6 月，歐盟委員會批准百時美施貴寶的 Yervoy 和 Opdivo 聯合用於治療惡性胸膜間皮瘤患者。同樣在 2022 年 6 月，再生元宣布計劃購買賽諾菲在賽諾菲-再生元合作夥伴 Ribtayo 中的股份，從而賦予該公司對該藥物的獨家全球開發、製造和商業化權利。此外，2020 年 5 月，吉利德科學和 Arrcus Biosciences 建立了為期 10 年的合作夥伴關係，共同商業化和共同開發 Arrcus 管道中當前和未來的治療候選藥物。 Arkas 目前對其範圍內的分子進行了 10 項臨床試驗，其中包括 3 種單克隆抗體。

隨著 COVID-19 在 2020 年 3 月的最後兩週在美國和歐洲達到臨界點，在各行各業都觀察到了其深遠的影響，醫院推遲或取消了癌症治療。並停止了臨床試驗.這在一定程度上阻礙了市場的增長。然而，隨著治療程序的恢復，製造商觀察到 2021 年下半年的業務穩步改善。

癌症單克隆抗體市場報告要點。

按產品類型，由於小鼠單克隆抗體的低成本、可用性和快速生產時間等因素，2021 年人類細分市場將佔據很大份額。然而，由於產品批准和產品發布的數量不斷增加，預計人形機器人細分市場將在預測期內保持最高的複合年增長率

由於血液系統疾病的患病率不斷增加以及強大的管道，血液系統癌症應用部門在 2021 年佔據了可觀的收入份額。此外，肺癌部分預計在預測期內以最高複合年增長率增長

2021 年，由於患者入院人數激增，醫院部分成為主要的最終用戶部分。此外，設施內創新藥物療法的可用性正在推動患者的偏好

由於主要市場參與者的戰略行動、不斷上升的癌症病例以及該地區政府的支持舉措，2021 年全球市場由北美主導

在亞太地區，由於國際和國家合作的增加，尤其是發達國家和發展中國家實體之間的合作，預計未來市場將顯著增長

內容

第一章研究方法

  • 信息採購
  • 數據分析

第 2 章執行摘要

  • 市場概況

第 3 章癌症單克隆抗體市場變量、趨勢和範圍

  • 市場系列展望
    • 母公司市場展望
    • 輔助市場展望
  • 繪製滲透率和增長前景
  • 市場細分和範圍
  • 癌症單克隆抗體市場分析市場動態
  • 市場驅動因素分析
    • 癌症患病率增加
    • 加大研發投入
    • 對個性化醫療的偏好不斷上升
  • 市場約束分析
    • 單克隆抗體治療成本高
  • 主要機會
    • 蓬勃發展的生物仿製藥市場
  • 癌症單克隆抗體市場 PESTLE 分析
  • 行業分析 - 搬運工
  • 分析重大交易和戰略聯盟
    • 合資企業
    • 併購
    • 許可和合作夥伴關係
    • 技術合作
    • 戰略撤資
  • COVID-19 影響分析

第 4 章癌症單克隆抗體市場：按類型分列的細分分析，2018-2030 年（十億美元）

  • 癌症單克隆抗體市場：類型變異分析
  • 人性化
  • 人類
  • 嵌合體
  • 老鼠

第 5 章癌症單克隆抗體市場：細分分析，按應用，2018-2030 年（十億美元）

  • 癌症單克隆抗體市場：應用變化分析
  • 血癌
  • 乳腺癌
  • 肺癌
  • 黑色素瘤
  • 結腸癌
  • 肝癌
  • 其他

第 6 章癌症單克隆抗體市場：細分分析，按最終用戶，2018-2030 年（十億美元）

  • 癌症單克隆抗體市場：最終用戶波動分析
  • 醫院
  • 調查
  • 其他

第 7 章癌症單克隆抗體市場：細分分析，按地區，2018-2030 年（十億美元）

  • 癌症單克隆抗體市場：區域差異分析
  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 法國
  • 亞太地區
    • 日本
    • 中國
    • 印度
  • 拉丁美洲
    • 巴西
    • 墨西哥
  • 中東和非洲 (MEA)
    • 南非
    • 沙特阿拉伯

第 8 章競爭格局

  • 供應商格局
    • 全球癌症單克隆抗體市場：2021 年主要參與者的市場份額分析
  • 公司簡介
    • F. HOFFMANN-LA ROCHE LTD
      • 公司簡介
      • 財務表現
      • 產品基準
      • 管道分析
      • 戰略舉措
    • 百時美施貴寶公司
      • 公司簡介
      • 財務表現
      • 產品基準
      • 管道分析
      • 戰略舉措
    • 默克公司
      • 公司簡介
      • 財務表現
      • 產品基準
      • 管道分析
      • 戰略舉措
    • 葛蘭素史克公司
      • 公司簡介
      • 財務表現
      • 產品基準
      • 管道分析
      • 戰略舉措
    • 強生&強生
      • 公司簡介
      • 財務表現
      • 產品基準
      • 管道分析
      • 戰略舉措
    • AMGEN, INC.
      • 公司簡介
      • 財務表現
      • 產品基準
      • 管道分析
      • 戰略舉措
    • 諾華公司
      • 公司簡介
      • 財務表現
      • 產品基準
      • 管道分析
      • 戰略舉措
    • 阿斯利康公司
      • 公司簡介
      • 財務表現
      • 產品基準
      • 管道分析
      • 戰略舉措
    • 禮來公司
      • 公司簡介
      • 財務表現
      • 產品基準
      • 管道分析
      • 戰略舉措
    • ABB VIE
      • 公司簡介
      • 財務表現
      • 產品基準
      • 管道分析
      • 戰略舉措
Product Code: GVR-4-68039-957-1

Cancer Monoclonal Antibodies Market Growth & Trends:

The global cancer monoclonal antibodies market size is expected to reach USD 159.7 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 11.2% from 2022 to 2030. The increasing prevalence of cancer, and product approvals along with a robust pipeline are the key factors augmenting the market growth. Furthermore, an increase in funding for R&D in this sector is expected to impact industrial growth. Moreover, the booming biosimilar market will further offer lucrative opportunities during the forecast period.

Non-small Cell Lung Cancer (NSCLC) is a common type of lung cancer. For patients with metastatic NSCLC, the prognosis is mostly poor, as only about 8% will live beyond 5 years after the diagnosis. Moreover, at present, there are no HER2-directed therapies approved precisely for treating HER2-mutant non-small cell lung cancer, which occurs in almost 2-4% of patients with non-squamous NSCLC. However, progress has been made over the last two years, mainly in the first-line setting, leaving a substantial unmet medical need. For instance, in April 2022, Daiichi Sankyo and AstraZeneca received acceptance of supplemental Biologics License Application (sBLA) of Enhertu in the U.S. for treating adult patients with unresectable NSCLC.

The development of monoclonal antibodies has been great both in clinical and technical research applications over the past three years. Given their advantages of safety, specificity, and efficacy, there is now prevalent acceptance of mAbs as advanced therapeutic agents. Cancer is the most dominating and important area of medicinal application, accounting for almost 50% of all monoclonal antibodies-related R&D programs.

In addition, in June 2021, the European Commission approved Bristol Myers Squibb's combination therapy of Yervoy and OPDIVO to treat patients for malignant pleural mesothelioma. In June 2022, Regeneron Pharmaceuticals, Inc. announced its plan to purchase Sanofi's stake in the Sanofi and Regeneron partnership on Libtayo, providing the company with exclusive global development, manufacturing, and commercialization rights to the medicine. Furthermore, in May 2020, Gilead Sciences, Inc. and Arcus Biosciences, Inc. entered into a 10-year partnership to co-commercialize and co-develop recent and future therapeutic candidates in Arcus's pipeline. Arcus has 10 current clinical studies of molecules in its range with three monoclonal antibodies.

As COVID-19 reached a tipping point in the U.S. and Europe during the last two weeks of March 2020, its far-reaching consequences were observed across industries and businesses, with hospitals postponing or canceling treatment procedures for cancer and halting clinical trials. This has hampered the market growth to an extent. However, as treatment procedures resumed, manufacturers observed a steady improvement in business in the second half of 2021.

Cancer Monoclonal Antibodies Market Report Highlights:

  • By type, the humanized segment held a larger share of the market in 2021 owing to factors such as, low cost, availability, and quick production time for mouse monoclonal antibodies. However, the human segment is expected to hold the highest CAGR during the forecast period due to an increase in the number of product approvals and product launches
  • The blood cancer application segment held a significant revenue share in 2021 owing to an increase in the prevalence of hematological disorders along with a robust pipeline. In addition, the lung cancer segment is poised to expand at the highest CAGR during the forecast period
  • In 2021, the hospital segment was the leading end-user segment due to an upsurge in the number of patient hospitalizations. In addition, the availability of innovative drug therapies in the facility drives the patient preference
  • North America dominated the global market in 2021, due to the strategic activities of key market players, increasing cancer cases, and supportive government efforts in this region
  • In Asia Pacific, the market is expected to grow considerably in the future due to the increasing number of international and national collaborations among entities, especially those in developed and developing countries

Table of Contents

Chapter 1 Research Methodology

  • 1.1 Information Procurement
  • 1.2 Data Analysis

Chapter 2 Executive Summary

  • 2.1 Market Snapshot

Chapter 3 Cancer Monoclonal Antibodies Market Variables, Trends & Scope

  • 3.1 Market Lineage Outlook
    • 3.1.1 Parent market outlook
    • 3.1.2 Ancillary market outlook
  • 3.2 Penetration and Growth Prospect Mapping
  • 3.3 Market Segmentation & Scope
  • 3.4 Cancer Monoclonal Antibodies Market Analysis Market Dynamics
  • 3.5 Market Driver Analysis
    • 3.5.1 Growing prevalance of cancer
    • 3.5.2 Increasing investement in research and development
    • 3.5.3 Rising preference for personalized medicines
  • 3.6 Market Restraint Analysis
    • 3.6.1 High cost of monoclonal antiobdy therpaeutics
  • 3.7 Key Opportunities
    • 3.7.1 Booming Biosimilar market
  • 3.8 Cancer Monoclonal Antibodies Market - PESTLE analysis
  • 3.9 Industry Analysis - Porter's
  • 3.10 Major Deals & Strategic Alliances Analysis
    • 3.10.1 Joint ventures
    • 3.10.2 Mergers & acquisitions
    • 3.10.3 Licensing & partnership
    • 3.10.4 Technology collaborations
    • 3.10.5 Strategic divestments
  • 3.11 COVID-19 Impact Analysis

Chapter 4 Cancer Monoclonal Antibodies Market: Segment Analysis, by Type, 2018 - 2030 (USD Billion)

  • 4.1 Cancer Monoclonal Antibodies Market: Type Movement Analysis
  • 4.2 Humanized
    • 4.2.1 Humanized Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 4.3 Human
    • 4.3.1 Human Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 4.4 Chimeric
    • 4.4.1 Chimeric Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 4.5 Murine
    • 4.5.1 Murine Market Estimates And Forecasts, 2018 - 2030 (USD Billion)

Chapter 5 Cancer Monoclonal Antibodies Market: Segment Analysis, By Application, 2018 - 2030 (USD Billion)

  • 5.1 Cancer Monoclonal Antibodies Market: Application Movement Analysis
  • 5.2 Blood Cancer
    • 5.2.1 Blood Cancer Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 5.3 Breast Cancer
    • 5.3.1 Breast Cancer Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 5.4 Lung Cancer
    • 5.4.1 Lung Cancer Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 5.5 Melanoma
    • 5.5.1 Melanoma Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 5.6 Colorectal Cancer
    • 5.6.1 Colorectal Cancer Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 5.7 Liver Cancer
    • 5.7.1 Liver Cancer Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 5.8 Others
    • 5.8.1 Others Market Estimates And Forecasts, 2018 - 2030 (USD Billion)

Chapter 6 Cancer Monoclonal Antibodies Market: Segment Analysis, By End-User, 2018 - 2030 (USD Billion)

  • 6.1 Cancer Monoclonal Antibodies Market: End-User Movement Analysis
  • 6.2 Hospitals
    • 6.2.1 Hospitals Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 6.3 Research Institutes
    • 6.3.1 Research Institutes Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 6.4 Others
    • 6.4.1 Others Market Estimates And Forecasts, 2018 - 2030 (USD Billion)

Chapter 7 Cancer Monoclonal Antibodies Market: Segment Analysis, By Region, 2018 - 2030 (USD Billion)

  • 7.1 Cancer Monoclonal Antibodies Market: Regional Movement Analysis
  • 7.2 North America
    • 7.2.1 North America cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
    • 7.2.2 U.S.
      • 7.2.2.1 U.S. cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
    • 7.2.3 Canada
      • 7.2.3.1 Canada cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
  • 7.3 Europe
    • 7.3.1 Europe cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
    • 7.3.2 U.K.
      • 7.3.2.1 U.K. cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
    • 7.3.3 Germany
      • 7.3.3.1 Germany cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
    • 7.3.4 France
      • 7.3.4.1 France cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
  • 7.4 Asia Pacific
    • 7.4.1 Asia Pacific cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
    • 7.4.2 Japan
      • 7.4.2.1 Japan cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
    • 7.4.3 China
      • 7.4.3.1 China cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
    • 7.4.4 India
      • 7.4.4.1 India cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
  • 7.5 Latin America
    • 7.5.1 Latin America cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
    • 7.5.2 Brazil
      • 7.5.2.1 Brazil cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
    • 7.5.3 Mexico
      • 7.5.3.1 Mexico cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
  • 7.6 Middle East and Africa (MEA)
    • 7.6.1 MEA cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
    • 7.6.2 South Africa
      • 7.6.2.1 South Africa cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
    • 7.6.3 Saudi Arabia
      • 7.6.3.1 Saudi Arabia cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)

Chapter 8 Competitive Landscape

  • 8.1 Vendor Landscape
    • 8.1.1 Global Cancer Monoclonal Antibody Market: Key Company Market Share Analysis, 2021
  • 8.2 Company Profiles
    • 8.2.1 F. HOFFMANN-LA ROCHE LTD
      • 8.2.1.1 Company overview
      • 8.2.1.2 Financial performance
      • 8.2.1.3 Product benchmarking
      • 8.2.1.4 Pipeline analysis
      • 8.2.1.5 Strategic initiatives
    • 8.2.2 BRISTOL MYERS SQUIBB CO.
      • 8.2.2.1 Company overview
      • 8.2.2.2 Financial performance
      • 8.2.2.3 Product benchmarking
      • 8.2.2.4 Pipeline analysis
      • 8.2.2.5 Strategic initiatives
    • 8.2.3 MERCK & CO.
      • 8.2.3.1 Company overview
      • 8.2.3.2 Financial performance
      • 8.2.3.3 Product benchmarking
      • 8.2.3.4 Pipeline analysis
      • 8.2.3.5 Strategic initiatives
    • 8.2.4 GLAXOSMITHKLINE PLC
      • 8.2.4.1 Company overview
      • 8.2.4.2 Financial performance
      • 8.2.4.3 Product benchmarking
      • 8.2.4.4 Pipeline analysis
      • 8.2.4.5 Strategic initiatives
    • 8.2.5 JOHNSON & JOHNSON
      • 8.2.5.1 Company overview
      • 8.2.5.2 Financial performance
      • 8.2.5.3 Product benchmarking
      • 8.2.5.4 Pipeline analysis
      • 8.2.5.5 Strategic initiatives
    • 8.2.6 AMGEN, INC.
      • 8.2.6.1 Company overview
      • 8.2.6.2 Financial performance
      • 8.2.6.3 Product benchmarking
      • 8.2.6.4 Pipeline analysis
      • 8.2.6.5 Strategic initiatives
    • 8.2.7 NOVARTIS AG
      • 8.2.7.1 Company overview
      • 8.2.7.2 Financial performance
      • 8.2.7.3 Product benchmarking
      • 8.2.7.4 Pipeline analysis
      • 8.2.7.5 Strategic initiatives
    • 8.2.8 ASTRAZENECA PLC
      • 8.2.8.1 Company overview
      • 8.2.8.2 Financial performance
      • 8.2.8.3 Product benchmarking
      • 8.2.8.4 Pipeline analysis
      • 8.2.8.5 Strategic initiatives
    • 8.2.9 ELI LILLY AND COMPANY
      • 8.2.9.1 Company overview
      • 8.2.9.2 Financial performance
      • 8.2.9.3 Product benchmarking
      • 8.2.9.4 Pipeline analysis
      • 8.2.9.5 Strategic initiatives
    • 8.2.10 ABBVIE
      • 8.2.10.1 Company overview
      • 8.2.10.2 Financial performance
      • 8.2.10.3 Product benchmarking
      • 8.2.10.4 Pipeline analysis
      • 8.2.10.5 Strategic initiatives

List of Tables

  • TABLE 1 Cancer monoclonal antibodies market - Industry snapshot & key buying criteria
  • TABLE 2 Cancer monoclonal antibodies market, by type, 2018 - 2030 (USD Billion)
  • TABLE 3 Cancer monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
  • TABLE 4 Cancer monoclonal antibodies market, by end-user, 2018 - 2030 (USD Billion)
  • TABLE 5 Cancer monoclonal antibodies market, by region, 2018 - 2030 (USD Billion)
  • TABLE 6 North America cancer monoclonal antibodies market, by type, 2018 - 2030 (USD Billion)
  • TABLE 7 North America cancer monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
  • TABLE 8 North America cancer monoclonal antibodies market, by end-user, 2018 - 2030 (USD Billion)
  • TABLE 9 U.S. cancer monoclonal antibodies market, by type, 2018 - 2030 (USD Billion)
  • TABLE 10 U.S. cancer monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
  • TABLE 11 U.S. cancer monoclonal antibodies market, by end-user, 2018 - 2030 (USD Billion)
  • TABLE 12 Canada cancer monoclonal antibodies market, by type, 2018 - 2030 (USD Billion)
  • TABLE 13 Canada cancer monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
  • TABLE 14 Canada cancer monoclonal antibodies market, by end-user, 2018 - 2030 (USD Billion)
  • TABLE 15 Europe cancer monoclonal antibodies market, by type, 2018 - 2030 (USD Billion)
  • TABLE 16 Europe cancer monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
  • TABLE 17 Europe cancer monoclonal antibodies market, by end-user, 2018 - 2030 (USD Billion)
  • TABLE 18 U.K. cancer monoclonal antibodies market, by type, 2018 - 2030 (USD Billion)
  • TABLE 19 U.K. cancer monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
  • TABLE 20 U.K. cancer monoclonal antibodies market, by end-user, 2018 - 2030 (USD Billion)
  • TABLE 21 Germany cancer monoclonal antibodies market, by type, 2018 - 2030 (USD Billion)
  • TABLE 22 Germany cancer monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
  • TABLE 23 Germany cancer monoclonal antibodies market, by end-user, 2018 - 2030 (USD Billion)
  • TABLE 24 France cancer monoclonal antibodies market, by type, 2018 - 2030 (USD Billion)
  • TABLE 25 France cancer monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
  • TABLE 26 France cancer monoclonal antibodies market, by end-user, 2018 - 2030 (USD Billion)
  • TABLE 27 Asia Pacific cancer monoclonal antibodies market, by type, 2018 - 2030 (USD Billion)
  • TABLE 28 Asia Pacific cancer monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
  • TABLE 29 Asia Pacific cancer monoclonal antibodies market, by end-user, 2018 - 2030 (USD Billion)
  • TABLE 30 Japan cancer monoclonal antibodies market, by type, 2018 - 2030 (USD Billion)
  • TABLE 31 Japan cancer monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
  • TABLE 32 Japan cancer monoclonal antibodies market, by end-user, 2018 - 2030 (USD Billion)
  • TABLE 33 China cancer monoclonal antibodies market, by type, 2018 - 2030 (USD Billion)
  • TABLE 34 China cancer monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
  • TABLE 35 China cancer monoclonal antibodies market, by end-user, 2018 - 2030 (USD Billion)
  • TABLE 36 India cancer monoclonal antibodies market, by type, 2018 - 2030 (USD Billion)
  • TABLE 37 India cancer monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
  • TABLE 38 India cancer monoclonal antibodies market, by end-user, 2018 - 2030 (USD Billion)
  • TABLE 39 Latin America cancer monoclonal antibodies market, by type, 2018 - 2030 (USD Billion)
  • TABLE 40 Latin America cancer monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
  • TABLE 41 Latin America cancer monoclonal antibodies market, by end-user, 2018 - 2030 (USD Billion)
  • TABLE 42 Brazil cancer monoclonal antibodies market, by type, 2018 - 2030 (USD Billion)
  • TABLE 43 Brazil cancer monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
  • TABLE 44 Brazil cancer monoclonal antibodies market, by end-user, 2018 - 2030 (USD Billion)
  • TABLE 45 Mexico cancer monoclonal antibodies market, by type, 2018 - 2030 (USD Billion)
  • TABLE 46 Mexico cancer monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
  • TABLE 47 Mexico cancer monoclonal antibodies market, by end-user, 2018 - 2030 (USD Billion)
  • TABLE 48 MEA cancer monoclonal antibodies market, by type, 2018 - 2030 (USD Billion)
  • TABLE 49 MEA cancer monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
  • TABLE 50 MEA cancer monoclonal antibodies market, by end-user, 2018 - 2030 (USD Billion)
  • TABLE 51 South Africa cancer monoclonal antibodies market, by type, 2018 - 2030 (USD Billion)
  • TABLE 52 South Africa cancer monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
  • TABLE 53 South Africa cancer monoclonal antibodies market, by end-user, 2018 - 2030 (USD Billion)
  • TABLE 54 Saudi Arabia cancer monoclonal antibodies market, by type, 2018 - 2030 (USD Billion)
  • TABLE 55 South Abrabia cancer monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
  • TABLE 56 South Abrabia cancer monoclonal antibodies market, by end-user, 2018 - 2030 (USD Billion)

List of Figures

  • FIG. 1 Market Research Process
  • FIG. 2 Information Procurement
  • FIG. 3 Primary Research Pattern
  • FIG. 4 Market Research Approaches
  • FIG. 5 Value Chain Based Sizing & Forecasting
  • FIG. 6 QFD Modelling For Market Share Assessment
  • FIG. 7 Market summary 2022 (USD Billion)
  • FIG. 8 Market trends & outlook
  • FIG. 9 Market segmentation & scope
  • FIG. 10 Cancer monoclonal antibodies market analysis, 2018 - 2030 (USD Billion)
  • FIG. 11 Cancer monoclonal antibodies market dynamics
  • FIG. 12 Market driver relevance analysis (Current & future impact)
  • FIG. 13 Global pharmaceutical industry, 2014 - 2022 (USD Billion)
  • FIG. 14 Market restraint relevance analysis (Current & future impact)
  • FIG. 15 Key Opportunities
  • FIG. 16 Cancer monoclonal antibodies market PESTEL analysis
  • FIG. 17 Porter's Five Forces Analysis
  • FIG. 18 Cancer monoclonal antibodies market, type outlook key takeaways (USD Billion)
  • FIG. 19 Cancer monoclonal antibodies market: Type movement analysis (USD Billion)
  • FIG. 20 Humanized market estimates and forecasts, 2018 - 2030 (USD Billion)
  • FIG. 21 Human market estimates and forecasts, 2018 - 2030 (USD Billion)
  • FIG. 20 Chimeric market estimates and forecasts, 2018 - 2030 (USD Billion)
  • FIG. 21 Murine market estimates and forecasts, 2018 - 2030 (USD Billion)
  • FIG. 22 Cancer monoclonal antibodies market, application outlook key takeaways (USD Billion)
  • FIG. 23 Cancer M monoclonal antibodies market: Therapeutic application movement analysis (USD Billion)
  • FIG. 24 Blood cancer market estimates and forecasts, 2018 - 2030 (USD Billion)
  • FIG. 25 Breast cancer market estimates and forecasts, 2018 - 2030 (USD Billion)
  • FIG. 26 Lung cancer market estimates and forecasts, 2018 - 2030 (USD Billion)
  • FIG. 27 Melanoma market estimates and forecasts, 2018 - 2030 (USD Billion)
  • FIG. 28 Colorectal cancer market estimates and forecasts, 2018 - 2030 (USD Billion)
  • FIG. 29 Liver cancer market estimates and forecasts, 2018 - 2030 (USD Billion)
  • FIG. 30 Other applications market estimates and forecasts, 2018 - 2030 (USD Billion)
  • FIG. 31 Cancer monoclonal antibodies market, end-user outlook key takeaways (USD Billion)
  • FIG. 32 Cancer monoclonal antibodies market: End-user movement analysis (USD Billion)
  • FIG. 33 Hospitals market estimates and forecasts, 2018 - 2030 (USD Billion)
  • FIG. 34 Research Institutes market estimates and forecasts, 2018 - 2030 (USD Billion)
  • FIG. 35 Others market estimates and forecasts, 2018 - 2030 (USD Billion)
  • FIG. 36 Regional market place: Key takeaways (USD Billion)
  • FIG. 37 Cancer monoclonal antibodies market: Regional movement analysis (USD Billion)
  • FIG. 38 North America cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
  • FIG. 39 U.S. cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
  • FIG. 40 Canada cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
  • FIG. 41 Europe cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
  • FIG. 42 U.K. cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
  • FIG. 43 Germany cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
  • FIG. 44 France cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
  • FIG. 45 Asia Pacific cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
  • FIG. 46 Japan cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
  • FIG. 47 China cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
  • FIG. 48 India cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
  • FIG. 49 Latin America cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
  • FIG. 50 Brazil cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
  • FIG. 51 Mexico cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
  • FIG. 52 MEA cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
  • FIG. 53 South Africa cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
  • FIG. 54 Saudi Arabia cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)